FDA Investigator Benjamin J Smith

Benjamin J Smith has inspections in 1 countries as of 27 Oct 2023. Benjamin J Smith has collaborated with a combinined 3458 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
60
Last Inspection Date:
27 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
100000834
Country:
United States of America
Co-Investigator(s):
A Williams, Amanda L Baskin, Amber M Capello Jones, Amy S Graf, Andrace Lde Yampert, Andrea D Swingle, Andrew H Paeng, Art O Czabaniuk, Ava M Bowman, Azza Talaat, Barbara A Rusin, Bei Y He, Benjamin J Dastoli, Bernard P Heidt, Bleta Vuniqi, Bo Chi, PhD, Brentley S Collins, Brian D Garthwaite, Brittany M Lowe, Brooke K Higgins, Brooke K Seeman, Bruce, Burnell M Henry, Byungja E Marciante, Calvin K Cook, Caroline H Le, Catherine V Quinlan, CDR Kimberly Y Martin, CDR Sean T Creighton, Charles E Frelix, Charles I Ann, Charles L Zhou, Charles M Spyr, Chelsea J Falkowski, Chelsea J Snider, Cheng H Yen, Cheryl A Clausen, Christina L Bigham, Colleen Thomas, PhD, Constantin Y Philopoulos, Corrine M Carter, Crystal M Young Lewis, Cynthia L Aycock, Cynthia Li, Daniel J Gorski, Danny Tuntevski, David A Paterson, David J Gasparovich, David J Gsparovich, David L Duncan, Dawn C Olenjack, Debara R Reese, Debara Reese, Denise L Burosh, Dennis E Guilfoyle, PhD, Dennis R Hock, Dina A Tallman, Donald C Obenhuber, PhD, Douglas A Campbell, Downer, Dr. Abhijit Raha, PhD, Eboni S Funderburk, Emest F Bizjak, Emily J Orban, Enrico Joset Mangahis, Eric S Pittman, Etty Feller, Gary Durbiel Goldner, Geneve M Maxwell, Geneve M Parks, George G Calafactor, Hans T Meyers, Harperd, Helen B Ricalde, Howard Anderson, PhD, Ifueko Osemwota, James A Lane, James E Szelc, Jazmine N Still, Jean Blackston Hill, Jean Blackstone Hill, Jeffrey A Sommers, Jeffrey D Meng, Jennifer A Kemp, Jennifer L Schmidt, Joan A Loreng, Joneson, Jorge F Christian, Joris Vanloco, Joseph A Piechocki, Joseph R Strelnik, Juliane C Lessard, Karen M Montgomery (KMM), Kennita Riddick, Kimberly Lewandowski Walker, Kinh Q Mac, L'oreal F Walker, Lakshmi Narasimhan, PhD, Larry K Austin, Laureen M Geniusz, Lauren E Burke, Lauren E Sexton, Lauren Iacono Connors, PhD, LCDR Anastasia Mpiliafas Brown, Leigh Anne Myers, Lesley Maep Lutao, Lewis K Antwi, Lisa M Bellows, Lisa P Oakes, Luella J Rossi, Lynda L Lanning, Maria Gutierrez Lugo, PhD, Maribeth G Grattan, Maribeth G Niesen, Mark G Peterson, Marlon K Turner, Matt D Suedkamp, Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Melina Rodriguez Upton, Melissa J Garcia, Mercy Oyugi, Michael G Truchan, Michael Shanks, MS, Michael Y Philopoulos, Michele L Forster, PhD, Michele L Glendenning, Monica J Wilkins, Montgomery Montgomery, Karen M, Muna Algharibeh, Myra K Casey, Nailing Zhang, Nancy L Rolli, Neal D Singletary, PhD, Neali H Lucas, Nicholas L Paulin, Norman Wong, Patricia A Cochran, Patricia H Dlugosz, Patrick B Cummings, Patsy J Domingo, Paula A Trost, Peng Zhou, Phillip M Pontikos, Qiao Y Bobo, Rafeeq A Habeeb, Ralph A Erickson, Raymond T Oji, Rebecca E Dombrowski, Rebecca K Olin, Robert D Tollefsen, Robert J Ham, Robert M Barbosa, Rosanna M Goodrich, Rose M Ashley, Ryan J Benedict, Sandra A Boyd, Sanket N Patel, Sara M Onyango, Sarah B Tanksley, Sarah M Meng, Sarah M Napier, Sargum C Sood, Scott T Ballard, Sean R Bryd, Shannon A Gregory, Sidney B Priesmeyer, Simone E Pitts, State Agency, Steven E Bowen, PhD, Susan F Laska, MS, Susan M Jackson, Susan M North, Susan P Bruederle, Suyang Qin, Talmane J Fisher, Theodore N Sietsema, Thomas A Peter, Thomas J Arista, Thursaml, Thuy T Nguyen, LCDR, Timothy C Schell, Tina M Pawlowski, Travis S Bradley, Vera M Anderson, Vesa Vuniqi, Vickie L Adkins, Wayne E Seifert, Wenzheng Zhang, William D Tingley, William R Brubaker, Yangmin Ning, Yumi J Hiramine, Zhenzhen Liu, PhD

Benjamin J Smith's Documents

Publish Date Document Type Title
September, 2003 FDA 483 Response Applied Laboratories, Inc. - Form 483R, 2003-10-01
March, 2004 FDA 483 Response Applied Laboratories, Inc. - Form 483R, 2004-04-19
December, 2003 FDA 483 Vesta Pharmaceuticals, Inc. - Form 483, 2003-12-19
September, 2003 EIR Applied Laboratories, Inc. - EIR, 2003-09-30
August, 2003 FDA 483 Century Pharmaceuticals, Inc. - Form 483, 2003-08-07
May, 2005 EIR Elanco Clinton Laboratories - EIR, 2005-05-19
February, 2005 FDA 483 Flotec, Inc. - Form 483, 2005-02-15
May, 2005 EIR Applied Laboratories, Inc. - EIR, 2005-05-06
April, 2004 EIR Exelead, Inc. - EIR, 2004-04-21
March, 2003 FDA 483 Roche Diagnostics Operations, Inc. - Form 483, 2003-03-27
July, 2004 FDA 483 Baxter Pharmaceutical Solutions LLC - Form 483, 2004-07-01
December, 2004 FDA 483 Siemens Water Technologies Corporation - Form 483, 2004-12-01
March, 2003 EIR Roche Diagnostics Operations, Inc. - EIR, 2003-03-27
December, 2002 EIR Cook Incorporated - EIR, 2002-12-12
March, 2003 FDA 483 Response Roche Diagnostics Operations, Inc. - Form 483R, 2003-04-18
September, 2003 FDA 483 Applied Laboratories, Inc. - Form 483, 2003-09-30
November, 2005 FDA 483 Roche Diagnostics Operations, Inc. - Form 483, 2005-11-04
March, 2004 EIR Applied Laboratories, Inc. - EIR, 2004-03-26
March, 2004 FDA 483 Applied Laboratories, Inc. - Form 483, 2004-03-26
April, 2004 FDA 483 Exelead, Inc. - Form 483, 2004-04-21
March, 2004 FDA 483 Rush & Hebble Co., Inc. - Form 483, 2004-03-08
December, 2002 FDA 483 Response Cook Incorporated - Form 483R, 2002-12-13
December, 2002 FDA 483 Cook Incorporated - Form 483, 2002-12-12
January, 2006 FDA 483 Century Pharmaceuticals, Inc. - Form 483, 2006-01-25
December, 2005 FDA 483 Terumo Cardiovascular Systems Corporation - Form 483, 2005-12-09
April, 2004 FDA 483 Response Exelead, Inc. - Form 483R, 2004-05-21
December, 2003 EIR Eli Lilly and Company - EIR, 2003-12-05
May, 2005 FDA 483 Applied Laboratories, Inc. - Form 483, 2005-05-06
January, 2005 FDA 483 Hologic, Inc. - Form 483, 2005-01-25
September, 2005 FDA 483 Boston Scientific Corp - Form 483, 2005-09-12
May, 2005 FDA 483 Response Applied Laboratories, Inc. - Form 483R, 2005-05-16
May, 2003 EIR Labcorp Drug Development Inc. - EIR, 2003-05-28

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more